enGene Therapeutics Valuation Multiples

enGene Therapeutics is valued at $128M as of September 2026. In the last FY enGene Therapeutics reported revenue of - and EBITDA of ($123M).

enGene Therapeutics Overview

About enGene Therapeutics

enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.


Founded

2023

HQ

Canada

Employees

82

Website

engene.com

Financials (FY)

Revenue: -
EBITDA: ($123M)

Market Cap

$128M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

enGene Therapeutics Financials

enGene Therapeutics reported last fiscal year revenue of - and negative EBITDA of ($123M).

In the same fiscal year, enGene Therapeutics generated ($123M) in EBITDA losses and had net loss of ($117M).

Revenue (LTM)


enGene Therapeutics P&L

In the most recent fiscal year, enGene Therapeutics reported revenue of - and EBITDA of ($123M).

enGene Therapeutics is unprofitable as of last fiscal year, with EBITDA margin of - and net margin of -.

See analyst estimates for enGene Therapeutics
Last FY202620272028
EBITDA($123M)
Net Profit($117M)
Net Debt($25M)

Financial data powered by Morningstar, Inc.

enGene Therapeutics Stock Performance

enGene Therapeutics has current market cap of $128M.

Market Cap Evolution


enGene Therapeutics' stock price is $1.91.

enGene Therapeutics share price decreased by 72.0% in the last year.

enGene Therapeutics has an EPS (earnings per share) of $-1.75.

See more trading valuation data for enGene Therapeutics
Market CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$128M0.3%---72.0%$-1.75

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

enGene Therapeutics Valuation Multiples

enGene Therapeutics Financial Valuation Multiples

As of September 18, 2026, enGene Therapeutics has market cap of $128M.

enGene Therapeutics has a P/E ratio of (1.1x).

Last FY202620272028
P/E(1.1x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified enGene Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

enGene Therapeutics Operational KPIs

enGene Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.5M for the same period.

Access forward-looking KPIs for enGene Therapeutics
Last FY202620272028
Revenue per Employee$0.0M
Opex per Employee$1.5M

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

enGene Therapeutics Competitors

enGene Therapeutics competitors include Nyrada, Biomea Fusion, Orient Europharma Co, LENZ Therapeutics, Biosyent, vTv Therapeutics, Inovio Pharmaceuticals, BRIM Biotechnology, Naturland Holding and Tiziana Life Sciences.

Most enGene Therapeutics public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Nyrada------
Biomea Fusion-($62M)--(1.5x)(1.4x)
Orient Europharma Co$144M($1M)1.5x-(200.2x)-
LENZ Therapeutics$19M($91M)----
Biosyent$31M$9M4.1x2.7x14.5x10.9x
vTv Therapeutics-($33M)-1.5x(1.2x)-
Inovio Pharmaceuticals$65K($84M)1475.9x194.7x(1.1x)-
BRIM Biotechnology$172K($14M)552.2x589.9x(6.9x)-

This data is available for Pro users. Sign up to see all enGene Therapeutics competitors and their valuation data.

Start Free Trial

enGene Therapeutics VC Funding History

Before going public, enGene Therapeutics raised $25M in total equity funding, across 2 rounds.


enGene Therapeutics Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Jan-15Series BFonds de solidarité FTQ; Pharmstandard; Lumira Ventures; Inbio Ventures; Forbion Capital Partners$12M-enGene Inc., a Montréal-based biotechnology company, develops an innovative platform technology for delivering genes to cells lining the gastrointestinal tract. The company focuses on DNA-based therapeutics, with its lead product EG-12 consisting of carrier-DNA complexes for gut-localized expression of IL-10 to treat ulcerative colitis. On January 26, 2015, enGene closed a CAD 13.5 million (EUR 9.6 million, US$11.5 million) Series B financing round led by Forbion Capital Partners, with participation from Fonds de solidarité FTQ, Pharmstandard International S.A., and existing investor Lumira Capital via its Merck Lumira Biosciences Fund. Proceeds fund advancement of EG-12 into phase I/II clinical trials. Sander van Deventer from Forbion joined enGene's Board of Directors, bringing expertise in IBD and gene therapy.
Nov-13Series ALumira Ventures$13M-enGene is a pre-clinical stage biopharmaceutical company developing a platform technology for the robust delivery of nucleotides (DNA or RNA) to the gut. In August 2013, it completed an initial closing of a $13.25 million financing led by Lumira Capital via its Merck Lumira Biosciences Fund. The funds enabled enGene to relocate its headquarters to Montreal, Quebec, and progress toward clinical stage development.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About enGene Therapeutics

When was enGene Therapeutics founded?enGene Therapeutics was founded in 2023.
Where is enGene Therapeutics headquartered?enGene Therapeutics is headquartered in Canada.
How many employees does enGene Therapeutics have?As of today, enGene Therapeutics has over 82 employees.
Who is the CEO of enGene Therapeutics?enGene Therapeutics' CEO is Ronald Harold Wilfred Cooper.
Is enGene Therapeutics publicly listed?Yes, enGene Therapeutics is a public company listed on Nasdaq.
What is the stock symbol of enGene Therapeutics?enGene Therapeutics trades under ENGN ticker.
When did enGene Therapeutics go public?enGene Therapeutics went public in 2023.
Who are competitors of enGene Therapeutics?enGene Therapeutics main competitors include Nyrada, Biomea Fusion, Orient Europharma Co, LENZ Therapeutics, Biosyent, vTv Therapeutics, Inovio Pharmaceuticals, BRIM Biotechnology, Naturland Holding, Tiziana Life Sciences.
What is the current market cap of enGene Therapeutics?enGene Therapeutics' current market cap is $128M.
Is enGene Therapeutics profitable?No, enGene Therapeutics is not profitable.
How many companies enGene Therapeutics has acquired to date?enGene Therapeutics hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies enGene Therapeutics has invested to date?enGene Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to enGene Therapeutics

Lists including enGene Therapeutics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial